insights_auto
BT3 neden düştü? 6,90%?
Daha Ayrıntılı Bilgichevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
€0,78
arrow_downward
-6,90%(-0,058) 1G
2 Eki, 22:00:00 GMT+2 · EUR
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoBT3 ile ilgili en önemli analizler oluşturuluyor...
Açık
€0,78
Yüksek
€0,78
Düşük
€0,78
Piy. değ.
236,38 Mn
Ort. hacim
0,00
İşlem Hacmi
0,00
52 haftalık en yüksek
€1,69
52 haftalık en düşük
€0,78
Çalışan sayısı
75
Açık
€0,78
Yüksek
€0,78
Düşük
€0,78
Piy. değ.
236,38 Mn
Ort. hacim
0,00
İşlem Hacmi
0,00
52 haftalık en yüksek
€1,69
52 haftalık en düşük
€0,78
Çalışan sayısı
75
Haberler
Web kaynaklarından ve haber iş ortaklarından
Business Wire
·
43 dakika önce
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall Street
·
16 dakika önce
Halozyme Therapeutics (HALO) Brings Jim Daly Back To Its Board As Launch Focus Sharpens
MarketBeat
·
29 dakika önce
PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock
Profil
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Lineage Cell Therapeutics Inc hakkında